Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2014, Article ID 524517, 10 pages
Research Article

The GLP-1 Analogue Exenatide Improves Hepatic and Muscle Insulin Sensitivity in Diabetic Rats: Tracer Studies in the Basal State and during Hyperinsulinemic-Euglycemic Clamp

Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People’s Hospital Affiliated Shanghai Jiaotong University School of Medicine, Shanghai 200011, China

Received 14 August 2014; Revised 17 October 2014; Accepted 18 October 2014; Published 16 November 2014

Academic Editor: Bernard Portha

Copyright © 2014 Hui Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [11 citations]

The following is the list of published articles that have cited the current article.

  • Tae-Hyoung Kim, Mi-Kyung Kim, Ye-Hwang Cheong, Yu-Na Chae, Youngyi Lee, Sun-O Ka, Il-Hoon Jung, Chang-Yell Shin, Eun Ju Bae, and Moon-Ho Son, “Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes,” European Journal of Pharmacology, 2015. View at Publisher · View at Google Scholar
  • In-Kyung Jeong, “Extrapancreatic Effect of Glucagon like Peptide-1,” The Korean Journal of Medicine, vol. 89, no. 4, pp. 404–412, 2015. View at Publisher · View at Google Scholar
  • Wuquan Deng, Sheng Qiu, Gangyi Yang, and Bing Chen, “Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives,” Therapeutics And Clinical Risk Management, vol. 11, pp. 1153–1162, 2015. View at Publisher · View at Google Scholar
  • Qianying Yang, and Fang Wang, “Successful Pregnancy after Improving Insulin Resistance with the Glucagon-Like Peptide-1 Analogue in a Woman with Polycystic Ovary Syndrome: A Case Report and Review of the Literature,” Gynecologic and Obstetric Investigation, vol. 81, no. 5, pp. 477–480, 2016. View at Publisher · View at Google Scholar
  • Francesco Andreozzi, Franco Folli, Gregory Alexander Raciti, Cecilia Nigro, Gaia Chiara Mannino, Francesco Beguinot, Giorgio Sesti, Claudia Miele, Teresa Procopio, and Alberto M. Davalli, “The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism,” Journal of Translational Medicine, vol. 14, no. 1, 2016. View at Publisher · View at Google Scholar
  • M. M. Smits, L. Tonneijck, M. H. A. Muskiet, M. H. H. Kramer, D. L. Cahen, and D. H. van Raalte, “Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas,” Diabetes, Obesity and Metabolism, vol. 18, no. 3, pp. 224–235, 2016. View at Publisher · View at Google Scholar
  • Lei XiaoTian, Wu QiNan, Gan XiaGuang, Deng WuQuan, Chen Bing, and Liang ZiWen, “ Exenatide Activates the APPL1-AMPK-PPAR α Axis to Prevent Diabetic Cardiomyocyte Apoptosis ,” Journal of Diabetes Research, vol. 2016, pp. 1–10, 2016. View at Publisher · View at Google Scholar
  • Li Zhao, Zhen Cang, Honglin Sun, Xiaomin Nie, Ningjian Wang, and Yingli Lu, “Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.,” BMC endocrine disorders, vol. 17, no. 1, pp. 13, 2017. View at Publisher · View at Google Scholar
  • Tohru Hira, Ryoya Suto, Yuka Kishimoto, Sumiko Kanahori, and Hiroshi Hara, “Resistant maltodextrin or fructooligosaccharides promotes GLP-1 production in male rats fed a high-fat and high-sucrose diet, and partially reduces energy intake and adiposity,” European Journal of Nutrition, 2017. View at Publisher · View at Google Scholar
  • Joana Oliveira, Eva Lau, Davide Carvalho, and Paula Freitas, “Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports,” Journal of Medical Case Reports, vol. 11, no. 1, 2017. View at Publisher · View at Google Scholar
  • Francesco Bifari, Roberto Manfrini, Michele Dei Cas, Cesare Berra, Matteo Siano, Massimo Zuin, Rita Paroni, and Franco Folli, “Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH),” Pharmacological Research, vol. 137, pp. 219–229, 2018. View at Publisher · View at Google Scholar